Advertisement

Vitiligo pp 469-479 | Cite as

Beyond Guidelines

  • Tag S. Anbar
  • Rehab A. Hegazy
  • Amira A. Eid
Chapter

Abstract

The therapeutic plan must start from the shared decision of patient and medical doctor, taking into account that repigmentation, depigmentation, camouflage, or a combinatory approach should depend on localization, extent, and duration of the lesions. In repigmentation option, the available melanocytes useful for migration have to be evaluated, as well as in depigmentation or camouflage ones. An algorithm will support the physician in the modulation of the therapeutic plan.

References

  1. 1.
    Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159:1051–76.CrossRefGoogle Scholar
  2. 2.
    Madigan LM, Al-Jamal M, Hamzavi I. Exploring the gaps in the evidenced-based application of narrowband-UVB for the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2016;32:66–80.CrossRefGoogle Scholar
  3. 3.
    Meredith F, Abbott R. Vitiligo: an evidence-based update. Report of the 13th Evidence Based Update Meeting, 23 May 2013, Loughborough, U.K. Br J Dermatol. 2014;170:565–70.CrossRefGoogle Scholar
  4. 4.
    Parsad D, Pandhi R, Dogra S, et al. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol. 2004;50:63–7.CrossRefGoogle Scholar
  5. 5.
    Gan EY, Gahat T, Cario-Andre M, et al. Clinical repigmentation patterns in paediatric vitiligo. Br J Dermatol. 2016;  https://doi.org/10.1111/bjd.14635.
  6. 6.
    Anbar TS, El-Sawy AE, Attia SK, et al. Patterns of repigmentation in two cases of hypopigmented type of vitiligo. Photodermatol Photoimmunol Photomed. 2009;25:156–8.CrossRefGoogle Scholar
  7. 7.
    Ferguson B, Kunisada T, Aoki H, et al. Hair follicle melanocyte precursors are awoken by ultraviolet radiation via a cell extrinsic mechanism. Photochem Photobiol Sci. 2015;14:1179–89.CrossRefGoogle Scholar
  8. 8.
    Mull AN, Zolekar A, Wang YC. Understanding melanocyte stem cells for disease modeling and regenerative medicine applications. Int J Mol Sci. 2015;16:30458–69.CrossRefGoogle Scholar
  9. 9.
    Nishimura EK. Melanocyte stem cells: a melanocyte reservoir in hair follicles for hair and skin pigmentation. Pigment Cell Melanoma Res. 2011;24:401–10.CrossRefGoogle Scholar
  10. 10.
    Goldstein NB, Koster MI, Hoaglin LG, et al. Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors. J Invest Dermatol. 2015;135:2068–76.CrossRefGoogle Scholar
  11. 11.
    Gauthier Y, Anbar T, Lepreux S, et al. Possible mechanisms by which topical 5-Fluorouracil and dermabrasion could induce pigment spread in vitiligo skin: an experimental study. ISRN Dermatol. 2013;2013:852497.  https://doi.org/10.1155/2013/852497.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Yu HS. Melanocyte destruction and repigmentation in vitiligo: a model for nerve cell damage and regrowth. J Biomed Sci. 2002;9:564–73.CrossRefGoogle Scholar
  13. 13.
    Tobin DJ, Swanson NN, Pittelkow MR, et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol. 2000;191:407–16.CrossRefGoogle Scholar
  14. 14.
    Kubanov A, Proshutinskaia D, Volnukhin V, et al. Immunohistochemical analysis of melanocyte content in different zones of vitiligo lesions using the Melan-A marker. Acta Dermatovenerol Alp Pannonica Adriat. 2016;25:5–9.Google Scholar
  15. 15.
    Davids LM, du Toit E, Kidson SH, et al. A rare repigmentation pattern in a vitiligo patient: a clue to an epidermal stem-cell reservoir of melanocytes? Clin Exp Dermatol. 2009;34:246–8.CrossRefGoogle Scholar
  16. 16.
    Falabella R. Vitiligo and the melanocyte reservoir. Indian J Dermatol. 2009;54:313–8.CrossRefGoogle Scholar
  17. 17.
    Hamzavi I, Jain H, McLean D, et al. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140:677–83.CrossRefGoogle Scholar
  18. 18.
    Anbar TS, Abdel-Raouf H, Awad SS, et al. The hair follicle melanocytes in vitiligo in relation to disease duration. J Eur Acad Dermatol Venereol. 2009;23:934–9.CrossRefGoogle Scholar
  19. 19.
    Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol. 2001;44:999–1003.CrossRefGoogle Scholar
  20. 20.
    Anbar TS, Hegazy RA, Picardo M, et al. Beyond vitiligo guidelines: combined stratified/personalized approaches for the vitiligo patient. Exp Dermatol. 2014;23:219–23.CrossRefGoogle Scholar
  21. 21.
    Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for vitiligo. American Academy of Dermatology. J Am Acad Dermatol. 1996;35:620–6.CrossRefGoogle Scholar
  22. 22.
    Wu CS, Yu CL, Lan CC, et al. Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol. 2004;13:755–63.CrossRefGoogle Scholar
  23. 23.
    Jung H, Oh ES. FK506 positively regulates the migratory potential of melanocyte-derived cells by enhancing syndecan-2 expression. Pigment Cell Melanoma Res. 2016.  https://doi.org/10.1111/pcmr.12480.
  24. 24.
    Anbar T, Westerhof W, Abdel-Rahman A, et al. Treatment of periungual vitiligo with erbium-YAG-laser plus 5-flurouracil: a left to right comparative study. J Cosmet Dermatol. 2006;5:135–9.CrossRefGoogle Scholar
  25. 25.
    Anbar TS, Westerhof W, Abdel-Rahman AT, et al. Effect of one session of ER:YAG laser ablation plus topical 5Fluorouracil on the outcome of short-term NB-UVB phototherapy in the treatment of non-segmental vitiligo: a left-right comparative study. Photodermatol Photoimmunol Photomed. 2008;24:322–9.  https://doi.org/10.1111/j.1600-0781.2008.00385.x.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Tan ES, Sarkany R. Topical monobenzyl ether of hydroquinone is an effective and safe treatment for depigmentation of extensive vitiligo in the medium term: a retrospective cohort study of 53 cases. Br J Dermatol. 2015;172:1662–4.CrossRefGoogle Scholar
  27. 27.
    AlGhamdi KM, Kumar A. Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol. 2011;25:749–57.CrossRefGoogle Scholar
  28. 28.
    Komen L, Zwertbroek L, Burger SJ, et al. Q-switched laser depigmentation in vitiligo, most effective in active disease. Br J Dermatol. 2013;169:1246–51.CrossRefGoogle Scholar
  29. 29.
    Rao J, Fitzpatrick RE. Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg. 2004;30:1043–5.Google Scholar
  30. 30.
    Majid I, Imran S. Depigmentation therapy with Q-switched Nd:YAG laser in universal vitiligo. J Cutan Aesthet Surg. 2013;6:93–6.CrossRefGoogle Scholar
  31. 31.
    van Geel N, Depaepe L, Speeckaert R. Laser (755 nm) and cryotherapy as depigmentation treatments for vitiligo: a comparative study. J Eur Acad Dermatol Venereol. 2015;29:1121–7.CrossRefGoogle Scholar
  32. 32.
    Hossain C, Porto DA, Hamzavi I, et al. Camouflaging agents for vitiligo patients. J Drugs Dermatol. 2016;15:384–7.PubMedGoogle Scholar
  33. 33.
    Kaliyadan F, Kumar A. Camouflage for patients with vitiligo. Indian J Dermatol Venereol Leprol. 2012;78(1):8–15.CrossRefGoogle Scholar
  34. 34.
    Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25:E1–13.CrossRefGoogle Scholar
  35. 35.
    Ukoha UT, Sosa JJ, Hynan LS, et al. Assessment of vitiligo severity: patient-reported estimates are not accurate. Br J Dermatol. 2015;173:1325–6.CrossRefGoogle Scholar
  36. 36.
    Quevedo WCJ, Holstein TJ. General biology of mammalian pigmentation. In: Nordlind JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne J, editors. The pigmentary system. 2nd ed. Oxford: Blackwell Publishing Ltd; 2006. p. 63–90.Google Scholar
  37. 37.
    Gauthier Y, Cario Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res. 2003;16:322–32.CrossRefGoogle Scholar
  38. 38.
    Ortonne J, Passeron T. Vitiligo and other disorders of hypopigmentation. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. Philadelphia: Elsevier; 2012. p. 1023–48.Google Scholar
  39. 39.
    Benzekri L, Gauthier Y, Hamada S, et al. Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo. Br J Dermatol. 2013;168:265–71.CrossRefGoogle Scholar
  40. 40.
    Benzekri L, Hmamouchi I, Gauthier Y. Possible patterns of epidermal melanocyte disappearance in nonsegmental vitiligo: a clinicopathological study. Br J Dermatol. 2015;172:331–6.CrossRefGoogle Scholar
  41. 41.
    Regazzetti C, Joly F, Marty C, et al. Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients. J Invest Dermatol. 2015;135:3105–14.CrossRefGoogle Scholar
  42. 42.
    Wagner RY, Luciani F, Cario-Andre M, et al. Altered E-cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo. J Invest Dermatol. 2015;135:1810–9.CrossRefGoogle Scholar
  43. 43.
    Rogers LC, Bevilacqua NJ, Armstrong DG, et al. Digital planimetry results in more accurate wound measurements: a comparison to standard ruler measurements. J Diabetes Sci Technol. 2010;4:799–802.CrossRefGoogle Scholar
  44. 44.
    van Geel N, Speeckaert R, De Wolf J, et al. Clinical significance of Koebner phenomenon in vitiligo. Br J Dermatol. 2012;167:1017–24.CrossRefGoogle Scholar
  45. 45.
    El-Din Anbar T, Abdel-Rahman AT, El-Khayyat MA, et al. Vitiligo on anterior aspect of neck in Muslim females: case series. Int J Dermatol. 2008;47:178–9.CrossRefGoogle Scholar
  46. 46.
    Cavalie M, Ezzedine K, Fontas E, et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135:970–4.CrossRefGoogle Scholar
  47. 47.
    Bhatnagar A, Kanwar AJ, Parsad D, et al. Psoralen and ultraviolet A and narrow-band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: an open prospective comparative study. J Eur Acad Dermatol Venereol. 2007;21:1381–5.CrossRefGoogle Scholar
  48. 48.
    Radakovic-Fijan S, Furnsinn-Friedl AM, Honigsmann H, et al. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 2001;44:814–7.CrossRefGoogle Scholar
  49. 49.
    Taieb A, Alomar A, Bohm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2012;168:5–19.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Tag S. Anbar
    • 1
  • Rehab A. Hegazy
    • 2
  • Amira A. Eid
    • 3
  1. 1.(in memory) Department of Dermatology and Andrology, Faculty of MedicineAl Minya UniversityAl MinyaEgypt
  2. 2.Department of Dermatology, Faculty of MedicineCairo UniversityCairoEgypt
  3. 3.Department of Dermatology, Venereology and Andrology, Faculty of MedicineAlexandria UniversityAlexandriaEgypt

Personalised recommendations